Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 300.00
Ask: 310.00
Change: -7.00 (-2.36%)
Spread: 10.00 (3.333%)
Open: 300.00
High: 290.00
Low: 290.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preclinical Results at ASGCT Annual Meeting

21 May 2018 07:00

RNS Number : 6263O
MaxCyte, Inc.
21 May 2018
 

 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Correction of Sickle Cell Disease Mutation in Hematopoietic Stem Cells

 

- Data demonstrate the potential of MaxCyte's technologies in non-viral CRISPR gene correction for the treatment of sickle cell disease

 

Gaithersburg, Maryland - 21 May 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, today announced that preclinical data for its non-viral CRISPR-mediated gene-correction of sickle cell mutation in hematopoietic stem cells (HSC) from a sickle cell disease (SCD) patient were presented at the annual meeting of the American Society of Gene and Cell Therapy (ASGCT) in Chicago on Friday, 18 May 2018.

 

The new data were presented in a poster presentation, entitled "GMP-compliant non-viral CRISPR-mediated process correcting the sickle cell disease mutation in SCD patient CD34+ cells achieves 60% wild type adult hemoglobin expression in differentiated erythrocytes." The data from work with the National Institutes of Health's (NIH) National Heart Lung and Blood Institute (NHLBI) demonstrated the potential of MaxCyte's technologies and the non-viral CRISPR gene correction in the treatment of SCD.

 

"We're encouraged that MaxCyte's technology is at the forefront of enabling non-viral CRISPR-mediated correction of disease mutations at clinically-relevant levels," said Doug Doerfler, MaxCyte Chief Executive Officer. "We're excited by these results for their potential to bring therapeutic benefit to individuals living with SCD."

 

The abstract can be found at the ASGCT meeting website at annualmeetingasgct.com/am18/abstracts and the presentation is available via https://www.maxcyte.com/resource-center/posters-presentations/.

 

About Sickle Cell Disease

 

According to the NHLBI, sickle cell disease (SCD) describes a group of inherited red blood cell disorders. Patients with SCD have abnormal hemoglobin, called hemoglobin S or sickle hemoglobin, in their red blood cells. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. Those who have SCD inherit two abnormal hemoglobin genes, one from each parent. In all forms of SCD, at least one of the two abnormal genes cause a person's body to make hemoglobin S.

 

Sickle cell disease is a life-long illness. The severity of the disease varies widely from person to person. In high-income countries like the United States, according to NHLBI, the life expectancy of a person with SCD is now about 40-60 years. Currently, hematopoietic stem cell transplantation (HSCT) is the only cure for SCD. Unfortunately, most people with SCD are either too old for a transplant or don't have a relative who is a good enough genetic match for them to act as a donor. A well-matched donor is needed to have the best chance for a successful transplant. While there are some treatments that can reduce symptoms and prolong life, more medical options are needed.

 

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with nine of the top ten global biopharmaceutical companies, and has more than 50 partnered programme licences in cell therapy including more than 20 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.

 

 For more information, visit www.maxcyte.com.

 

 

###

 

For further information, please contact:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

 

+1 301 944 1660

Nominated Adviser and Broker

Panmure Gordon

Freddy Crossley

Emma Earl

Ryan McCarthy

James Stearns

 

 

+44 (0)20 7886 2500

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABSGDULDBBGII
Date   Source Headline
11th Jan 20217:00 amRNSMyeloid Therapeutics Clinical & Commercial License
23rd Dec 20207:00 amRNSTrading Update
9th Nov 20201:00 pmRNSCARMA Cell Therapies at SITC 2020
9th Nov 20207:00 amRNSPresentations at Upcoming Virtual IR Conferences
2nd Nov 20203:52 pmRNSResult of AGM
22nd Oct 20206:22 pmRNSDisclosure of Remuneration for Non-Audit Services
14th Oct 20207:00 amRNSNotification of AGM and Audit Declaration
13th Oct 20207:00 amRNSMaxCyte announces leadership appointments
1st Oct 20207:00 amRNSDirector/PDMR Shareholding
21st Sep 20207:00 amRNSResults for the Six Months ended 30 June 2020
10th Sep 20201:42 pmRNSGrant of options
10th Sep 20207:00 amRNSHC Wainright & Co Virtual Conference Presentation
9th Sep 20207:00 amRNSAppointment of Amanda L. Murphy as CFO
2nd Sep 20202:57 pmRNSHolding(s) in Company
2nd Sep 20207:00 amRNSNotice of Half Year Results
18th Aug 20207:00 amRNSExpansion of CARMA’s Phase I Trial of MCY-M11
14th Aug 20207:00 amRNSHolding(s) in Company
16th Jul 20206:04 pmRNSDirector Dealings and Issue of Equity
15th Jul 20207:00 amRNSTrading Update
8th Jul 20207:00 amRNSAPEIRON Biologics Clinical and Commercial License
1st Jul 20207:00 amRNSBlock Listing Return & TVR
2nd Jun 20205:54 pmRNSHolding(s) in Company
28th May 20203:34 pmRNSHolding(s) in Company
26th May 20205:49 pmRNSHolding(s) in Company
26th May 20204:22 pmRNSHolding(s) in Company
26th May 20203:45 pmRNSHoldings in Company
21st May 20201:50 pmRNSResult of Special Meeting and Issue of Equity
14th May 20207:00 amRNSPoster Presentation on MCY-M11 at ASCO 2020
7th May 20207:00 amRNSLicense Agreement with Caribou Biosciences
1st May 20207:00 amRNSResult of Offering
30th Apr 20205:39 pmRNSProposed Offering to raise up to £25.1 million
21st Apr 20207:00 amRNSFinal Results for Year Ended 31 December 2019
9th Apr 20207:00 amRNSBusiness Update Related to COVID-19 Pandemic
24th Mar 20207:00 amRNSLicense Agreement with Allogene Therapeutics
21st Feb 20207:00 amRNSConsolidation of Trading Lines
20th Feb 20206:18 pmRNSAIM Block Admission Return / Total Voting Rights
5th Feb 20207:00 amRNSMaxCyte to Present at BIO CEO & Investor Conf
24th Jan 20204:31 pmRNSGrant Of Options
22nd Jan 20205:15 pmRNSHolding(s) in Company
22nd Jan 20205:11 pmRNSHolding(s) in Company
22nd Jan 20205:08 pmRNSHolding(s) in Company
20th Jan 20207:00 amRNSTrading Update
19th Dec 20197:00 amRNSNew Executive Vice President and Trial Update
16th Dec 20195:25 pmRNSDirector/PCA transaction initial notification
4th Dec 20197:00 amRNSAgreement with KSQ Therapeutics
21st Nov 20197:00 amRNSVor Biopharma Clinical and Commercial License
14th Nov 20197:00 amRNSPresentation at Jefferies Healthcare Conference
7th Nov 20197:00 amRNSMaxCyte to Present at BIO-Europe 2019
1st Nov 20191:04 pmRNSResult of AGM
24th Oct 20197:00 amRNSMaxCyte Advances Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.